Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling

Thrombosis and Haemostasis

Volumn 104, Issue 5, 2010, Pages 875-885

  Colman, Robert W ^a   Wu, Yi ^a   Liu, Yuchuan ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contact phase; Cytokines; Endothelial cells; Tissue factor factor VII; Urokinase receptor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BETA3 INTEGRIN; BRADYKININ; CAVEOLIN 1; HIGH MOLECULAR WEIGHT KININOGEN; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; CANCER CELL; CAVEOLA; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CONFORMATION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 78149486483     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0017     Document Type: Conference Paper

References (54)

1. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-613.
2. Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood 1965; 26: 521-532.
3. Colman RW. Contributions of Mayme Williams to the Elucidation of the Multiple Functions of Plasma Kininogens. Thromb Haemost 1992; 68: 99-101.
4. Thompson RE, Mandle R Jr, Kaplan AP. Studies of binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci USA 1979; 76: 4862-4866.
5. Raja SN, Campbell JN, Mayer RA, et al. Role of kinins in pain and hyperalgesia: Psychophysical studies in a patient with kininogen deficiency. Clin Sci 1992; 83: 337-341.
6. Colman RW, Schmaier AH. Contact System: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-3843.
7. Zhao Y, Qiu Q, Mahdi F, et al. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol. 2001; 280: H1821-H1829.
8. Colman RW, Jameson BA, Lin Y, et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-550.
9. Cao DJ, Guo Y-L, Colman R W. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res 2004; 94: 1227-1234.
10. Asakura SYW, Sottile J, Zhang Q, et al. Opposing effects of low and high molecular weight kininogens on cell adhesion. J Biochem (Tokyo) 1998; 124: 473-484.
11. Colman RW, Najamunnisa S, Yan W, et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-1487.
12. Pike LJ. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res 2006; 47: 1597-1598.
13. Frank PG, Woodman SE, Park DS, et al. Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol 2003; 23: 1161-1168.
14. Sonveaux P, Martinive P, DeWever J, et al. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res 2004; 95: 154-161.
15. Griffoni CSE, Santi S, Riccio M, et al. Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 2000; 276: 756-761.
16. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002; 115: 3729-3738.
17. Alain P RF, Monique L, Arbeillec B, et al. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res 2001; 262: 28-36.
18. Ikeda S, Ushio-Fukai M, Zuo L, et al. Novel role of ARF6 in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 2005; 96: 467-475.
19. Wu Y, Rizzo V, Liu Y, et al. Kininostatin associated with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 2007; 9: 1968-1975.
20. Chapman HA, Wei Y, Simon DI, et al. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 1999; 82: 291-297.
21. Pampori N, Hato T, Stupack DG, et al. Mechanisms and consequences of affinity modulation of integrin alpha Vbeta 3 detected with a novel patch-engineered monovalent ligand. J Biol Chem 1999; 274: 21609-21616.
22. Suehiro K, Gailit J, Plow EF. Fibrinogen is a ligand for integrin alpha5beta1 on endothelial cells. J Biol Chem 1997; 272: 5360-5366.
23. Simon DI, Wei Y, Zhang L, et al. Identification of a urokinase receptor-integrin interaction site. promiscuous regulator of integrin function. J Biol Chem 2000; 275: 10228-10234.
24. Degryse B, Resnati M, Czekay R-P, et al. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem 2005; 280: 24792-24803.
25. Im E, Kazlauskas A. Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 2007; 282: 29122-29129.
26. Werdich XQ, Penn JS. Specific involvement of SRC family kinase activation in the pathogenesis of retinal neovascularisation. Investig Ophthalmol Vis Sci 2006; 47: 5047-5056.
27. Arias-Salgado EG, Lizano S, Sarkar S, et al. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci USA 2003; 100: 13298-13302.
28. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
29. Wie Y, Czekay RP, Robillard L, et al. Regulation of {alpha}5{beta}1 integrin conformation and function by urokinase receptor binding. J Cell Biol 2005; 168: 501-511.
30. Liu Y, Sainz IM, Wu Y, et al. The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved Kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases. Exp Cell Res 2008; 314: 774-788.
31. Colman RW, Jameson BY, Lin Y, et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-550.
32. Liu Y, Senger DR. Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells. FASEB J 2004; 18: 457-468.
33. Ischenko I, Guba M, Yezhelyev M, et al. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 2007; 10: 167-182.
34. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004; 23: 7918-7927.
35. Roskoski R Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005; 331: 1-14.
36. Duan LJ, Imamoto A, Fong GH. Dual roles of the C-terminal Src kinase (Csk) during developmental vascularisation. Blood 2004; 103: 1370-1372.
37. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004; 30: 31-44.
38. Herrick S, Blanc-Brude O, Gray A, et al. Fibrinogen. Int J Biochem Cell Biol 1999; 31: 741-746.
39. Wei Y, Tang CH, Kim Y, et al. Urokinase receptors are required for {alpha}5beta1 integrin-mediated signaling in tumor cells. J Biol Chem 2007; 282: 3929-3939.
40. Labrecque L, Nyalendo C, Langlois S, et al. Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem 2004; 279: 52132-52140.
41. Tarui T, Akakura N, Majumdar M, et al. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 2006; 95: 524-534.
42. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998; 273: 8502-8507.
43. Nguyen DH, Webb DJ, Catling AD, et al. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 2000; 275: 19382-19388.
44. Tang H, Kerins DM, Hao Q, et al. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 1998; 273: 18268-18272.
45. Kaneko T, Konno H, Baba M, et al. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003; 94: 43-49.
46. Conese M, Nykjaer A, Petersen CM, et al. α-2 Macroglobulin receptor/Ldl receptor-related protein (Lrp)-dependent internalization of the urokinase receptor. J Cell Biol 1995; 131: 1609-1622.
47. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997; 16: 2610-2620.
48. Barinka C, Parry G, Callahan J, et al. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 2006; 363: 482-495. (Pubitemid 44472493)
49. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311: 656-659. (Pubitemid 43191309)
50. Liu Y, Cao DJ, Sainz IM, et al. The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting uPA-uPAR complex and inhibiting its signaling and internalization. Am J Physiol Cell Physiol 2008; 5: C257-267.
51. Prager GW, Breuss JM, Steurer S, et al. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ Res 2004; 94:1562-1570.
52. Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikreinkinin system. From protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007; 98: 77-83.
53. Hassan S, Sainz IM, Khan MM, et al. The Antithrombotic Activity of Kininogen is Mediated by Inhibitory Effects of Domain 3 During Arterial Injury In Vivo. Am J Physiol Heart Circ Physiol 2007; 292: H2959-2965.
54. Blat Y, Seiffert D. A renaissance for the contact system in blood coagulation. Thromb Haemost 2008; 99: 457-460.